Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 631–640 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 631

    Medicine slug
    fluoxetine
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    171
    Source count
    168
    Agreement rate
    0.988095
    Recorded readings

    1. 8.6 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      166

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 166 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1c768b5-64bb-4036-aa92-797b3a5f92eb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1302fc08-d5fa-54b4-e063-6394a90a5275 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80e52273-9741-6aef-eb24-8a93ead85ba7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f89a5800-6fdb-4938-a28e-3bf1aeb1c21a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f8b1834-d5d7-72b6-d2ed-cb074344d59e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a32f1a0b-a9ee-883a-e053-2a95a90a8c12 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1409772-e719-67f5-e053-2995a90ab5b6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:369dbfba-9de4-433c-8680-2ec047b8f8d9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18e9f7f2-2d33-d139-e063-6294a90a3012 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ffe57c3-6f70-4075-aacb-d87a3990fdea (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c88f33ed-6dfb-4c5e-bc01-d8e36dd97299 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b9c2d73-866b-44c4-8718-e7e4a9a0fb55 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:851c4cfb-e1f0-4087-b13d-c07c25fea37d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c8970ad-2266-4653-b7eb-4c79ba926d89 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b07f9eab-44ac-4667-bd46-52d736daa5d6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d121146e-7439-4169-a421-dab7b882b8aa (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8666383-462d-4a21-8f49-1d572da386d1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3da881-475d-cdee-e063-6394a90aee99 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:992060ee-fb4e-4c6d-9ffe-30902bc63af2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0608d9-1ae3-43be-8a20-e9f34e955862 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583c5021-2948-7db4-e063-6294a90ae7dc (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5a267cb-08bd-4530-a7a8-2bceddd828e5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45454555-7402-41cb-a452-e6a76e04f387 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e15646e0-a431-4b3d-8d6f-7a3d0dadfcc6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78994632-74b3-951c-e053-2a91aa0ac1c8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4eeae3d-ae56-4e7e-b07d-02851f12039f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cba1992-3990-42a1-9d9a-77b593bbb02e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f917063a-226e-0978-e053-6294a90aeb4b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58b39e6a-3aae-4551-b081-586a4506aef2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb66a702-7670-4a73-98fb-0e63151a1ffb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca749349-d0e1-4b7c-b4c0-e392e72cf0f6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfae4357-b6f9-9a30-e053-2995a90a2667 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da6b9b19-2ea1-9a39-e053-2995a90ad730 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d34362ed-e821-4c55-9f8c-3dfb772b1b2a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a07ebe9-3661-4a48-b8af-9b228875166a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1b40d46-5233-49d7-9833-762cb6999012 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5020d0d6-969e-b4cd-e063-6294a90af9d2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fff3732-efc3-4cbd-a8fa-cde3181f03e6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50253c6e-de36-05e6-e063-6294a90ad7a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:023cef65-c9c2-4d70-af66-198fb1b57714 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54d9f02c-95ea-99b1-e063-6294a90a9140 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:647e17f5-a15a-4e77-922c-24a5db2118bc (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ccada47-7eb9-285d-5059-06afb4466114 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d5c10a-0cfc-4b89-942c-0fb5c67ae409 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da785a8a-d897-494e-9fd2-1d09b32f0190 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08f3c11c-9ba0-4c53-bf31-264725e611ea (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4915e22f-cecb-4261-8389-9bb417a20e82 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180a07fd-1f6a-4617-b8e0-f938c65ba273 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42c4c341-8282-4961-8581-8a0430162559 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a151528-2fe0-4059-b7b7-fcb4e80a51e3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06d71a33-5578-4012-b11d-764f45bc1e6a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3276a2a4-61c7-4de6-b519-3aa8b62da88f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f069b9b-16e4-4f0e-b420-4aa02ffbb632 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cca9edf9-2454-4bf9-98e8-c531a8f5dc42 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1c7ec04-dd9e-400f-8f49-e900945fc61c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7a4db7f-cdac-2b36-e053-2995a90a8d64 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b8fe00e-7a2f-486b-9b72-465a494d8939 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4abbd9d9-e9b1-463d-8f39-f3f50d80f58a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20516384-6517-48be-bd6e-718250878a76 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9965a672-7842-4926-9063-b76317c74862 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72e391aa-1a46-4589-8550-f83ac9241cf1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50369762-c7c3-d58e-e063-6294a90af8df (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d26f7450-7650-43df-a63b-1fe2472882a9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11544dea-2f5e-1536-584a-5d1f37a99770 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5336ce59-7a6c-4db9-8512-299cc5e599c0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6457d6e-5586-40e9-883d-352ee0527d80 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ebf287e-fc95-4a2c-a496-62c7cf6cbf38 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e8912e2-2a0c-5047-e063-6294a90a7e32 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd00b7f-df07-455f-e063-6394a90a1f10 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4831735-6731-473a-b4f0-1f4a67aa7120 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:096e9438-2bed-434b-aa56-a6d55471fef1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef0fa849-a3a0-45d2-9258-da2d46bee089 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:679e439a-d955-4b54-8236-a2ccd9a2a10a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d7a196b-91de-4753-8bb6-c6d5c668952d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53ac797d-8792-4a8c-9708-d1de3d377e8f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09fb3100-1e06-4cdc-8016-7e4f5d097490 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d09a5026-b3eb-403f-bf31-d5991a81a8ce (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0f00a25-1aec-42fd-a301-d3710ae3e1f3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70e115cc-6e9b-4b96-a1a9-779ed51ad0a7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5631bb72-798a-6efc-e054-00144ff8d46c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f302db0-1c88-44cf-8258-3c1c60afb5a4 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d5d03ff-0d0c-429f-b747-31ff3465d39d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cece294b-c414-4832-a8a2-22fb66aabda9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7ba9184-7dad-4f82-a947-bb2cc6b760ce (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:620ecf00-5473-4420-afd1-94b5b38e7301 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a08dadff-f209-48dc-b597-6f085be13640 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06394c4b-99f4-4257-bf29-53c170c5a061 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc754dff-cecb-fc6b-e053-6394a90ab371 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aae4e339-5244-f6f9-e053-2995a90a42ce (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ce2f189-4386-4d0d-84f6-6d913ad1c09b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faf4bc0c-bf65-4a65-8f08-3d800185d6a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50117d4f-0777-54d3-e063-6394a90a857c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7b102f0-17a2-49f7-b898-cb2e0fc71b4d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48705e4f-c3ee-af78-e063-6394a90ad052 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9ed97dd-8041-4a02-889c-dcb8b2805f36 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57f21f2b-0ec2-49dc-911a-806e5ae880c2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c56a437-f6bf-4ac8-b1d9-fc8a605a97e7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1226a67f-ec09-42f6-9d1b-9ddd862ea0a0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:390c61e6-14dd-4391-45b8-0fb5f4652723 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3195db14-0cae-4b49-9fba-49b869fe92a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a408c325-d2d5-4e88-85ce-96913eb58183 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dced86a0-fc08-465c-897c-f8899e6206d5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5035f61-693e-4386-8a07-3c36a6a46917 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3453755b-3ed6-47a3-b4c7-c64758e7784c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b8d8da5-8c06-0942-e053-2995a90aa2c9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80816531-9db3-492b-aebc-4681bf3c1554 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e822937-9431-446f-88c4-330a25d12439 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e7929f-dec4-467d-93c2-93360884e9e9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05b0781b-50e2-4311-bde0-430b96e2ef8e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdf3b608-e14c-474b-b80e-01ac5f701866 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb06af33-8ff7-0b02-0029-d628f62e1382 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5dc20c8f-0d8f-400c-b850-fe1b7e3e75e3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a2a5194-b793-4c62-a177-040dad38526b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9de93d4-2edc-2838-e053-2995a90a8ed6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32afb28a-dc4c-4a7e-9701-1825f805e7df (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77b6ae48-8e3a-42e6-9b5a-aeed750861e8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a04a5bed-d051-4bb4-ae20-b09b10d5c181 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10293946-5a06-4c21-9f78-941be360b09b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3daecd20-6a59-44d3-8269-4912214c08b4 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70b4bd1b-d355-189e-a414-9fff182fd1cd (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ded68c-1d2e-453d-b155-84c3102e1f0e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5fa64a6-3de3-4e2e-8b92-6d507fb8eee9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e111be4-28f0-c290-e063-6294a90a447f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac1651cc-4a2e-47cf-8a7e-be7ddcaf9f31 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f274f102-67ec-46e7-b248-533be2e3003b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9651816f-58f5-4bf8-8183-6f3d84d36b5c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5d49dee-a7de-44d8-80b5-1aeb89e76938 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7553d708-22a0-44ea-b907-7a86f2657f4c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be2e4325-feb9-4957-99c0-0a741a2d71a0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be4c5102-e0aa-3b89-e053-2a95a90a5d9d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9de65da4-73f8-4c88-8198-c92e63224ddb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e1e767b-66a5-4f38-8142-84d40d447f92 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab1eec9d-f755-81a2-e053-2a95a90acb3c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4dee4a1a-360c-532e-e063-6394a90a8426 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4043133-38de-4faa-bb76-8fafa5913844 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bee936b-0130-4a6b-a974-956aef5486d9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24926986-7552-4f1a-8366-f035bbd07104 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23899405-007b-48d9-82a9-a530b8e90784 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0259db51-e1ff-6e7a-e063-6394a90abace (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fba8d68-0663-4053-93ee-7531246fd47d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02283de9-6087-45f7-a9ce-3b082ce860de (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:224c8c17-0183-4cd7-ab9e-0062f3c624f0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef699ed0-fd9e-4580-93bb-6fd50499dbd1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06582152-d7d3-4e87-8c13-a4416a6ec927 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7bea6e9-cf90-a963-e053-2a95a90a1068 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a631271-9597-42a4-a924-1d06ecaba8c8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      149. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76b264ce-2a13-4511-8e21-4ffad0a327f9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      150. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a48124-0790-51c2-e053-2a95a90aa1af (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      151. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cac17277-3481-4661-935f-efc48fff534c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      152. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:daf33244-1348-4c34-b44c-9e35d5c48a3e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      153. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e83e2220-d32a-472c-bd9f-b87d0cf8858f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      154. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51b8e791-4e9a-4014-b4d8-68fd51ca889f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      155. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5386a140-7c5b-5959-e063-6294a90a2ad0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      156. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:887fc670-db67-4cfe-967b-46b38375dae5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      157. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec608267-9c00-4d5c-a9ed-d89503f93d28 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      158. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:651e8c32-4519-4619-854f-4be03c6240b6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      159. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4cbf9a9-1d7f-4aa0-a18d-fba50d49bd2b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      160. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:578ca8f8-86eb-4247-a0b3-50c3837a982e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      161. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97960730-432e-4e94-bb4e-62a3157270a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      162. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd659085-c32d-4d35-9d4b-bafa2a93f1fb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      163. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:493a5946-e750-4500-afd1-8f3fdc1d420e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      164. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50345702-9869-5335-e054-00144ff88e88 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      165. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4f37ef1-8f5e-4318-90f1-2d8f8afb669c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.
      166. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e6b9d55-f9bb-4bf2-bc6c-975cc0d94d23 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Its mean terminal half-life after a single dose was 8.6 days and after multiple dosing was 9.3 days.

    2. 100 to 300 hours

      Numeric value
      100
      Unit
      hours
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcebc7cf-6f95-4f7a-a22b-c7d2e0f04d74 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        8.0 (2.0 to 10.0) 722.4 (138) 26.5 (15.7 to 310.0) Norfluoxetine 9.7 (37) 48.0 (11.0 to 144.0) 2114.3 (41) 110.4 (66.8 to 308.0) a) 3 subjects had longer fluoxetine elimination half-life values ranging from 100 to 300 hours; see Clinical issues relating to metabolism/elimination for more information on "poor metabolizers" Food does not appear to affect the systemic bioavailability of fluoxetine, a

    3. 4 to 16 days

      Numeric value
      Not parsed
      Unit
      Not recorded
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4527c502-b28c-449f-ad2d-7daf21563cfa (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        ination of fluoxetine (elimination half life of 1 to 3 days after acute administration and 4 to 6 days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4 to 16 days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady state, even when a fixed dose is used [s

  2. Projected row 632

    Medicine slug
    fluoxetine
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    171
    Source count
    129
    Agreement rate
    1
    Recorded readings

    1. 94.5%

      Numeric value
      94.5
      Unit
      %
      Source records
      129

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 129 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1c768b5-64bb-4036-aa92-797b3a5f92eb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80e52273-9741-6aef-eb24-8a93ead85ba7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f89a5800-6fdb-4938-a28e-3bf1aeb1c21a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f8b1834-d5d7-72b6-d2ed-cb074344d59e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:369dbfba-9de4-433c-8680-2ec047b8f8d9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18e9f7f2-2d33-d139-e063-6294a90a3012 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ffe57c3-6f70-4075-aacb-d87a3990fdea (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding - Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound invitro to human serum proteins, including albumin and α 1 -glycoprotein.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c88f33ed-6dfb-4c5e-bc01-d8e36dd97299 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b9c2d73-866b-44c4-8718-e7e4a9a0fb55 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:851c4cfb-e1f0-4087-b13d-c07c25fea37d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c8970ad-2266-4653-b7eb-4c79ba926d89 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b07f9eab-44ac-4667-bd46-52d736daa5d6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8666383-462d-4a21-8f49-1d572da386d1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:992060ee-fb4e-4c6d-9ffe-30902bc63af2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0608d9-1ae3-43be-8a20-e9f34e955862 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding - Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5a267cb-08bd-4530-a7a8-2bceddd828e5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45454555-7402-41cb-a452-e6a76e04f387 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78994632-74b3-951c-e053-2a91aa0ac1c8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cba1992-3990-42a1-9d9a-77b593bbb02e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ada19ae4-f3bd-47fa-a5c3-a6bb3aa34943 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 ‑glycoprotein.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58b39e6a-3aae-4551-b081-586a4506aef2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding: Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb66a702-7670-4a73-98fb-0e63151a1ffb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca749349-d0e1-4b7c-b4c0-e392e72cf0f6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding Over the concentration range from 200 ng/mL to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfae4357-b6f9-9a30-e053-2995a90a2667 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da6b9b19-2ea1-9a39-e053-2995a90ad730 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d34362ed-e821-4c55-9f8c-3dfb772b1b2a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1b40d46-5233-49d7-9833-762cb6999012 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fff3732-efc3-4cbd-a8fa-cde3181f03e6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50253c6e-de36-05e6-e063-6294a90ad7a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54d9f02c-95ea-99b1-e063-6294a90a9140 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:647e17f5-a15a-4e77-922c-24a5db2118bc (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ccada47-7eb9-285d-5059-06afb4466114 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da785a8a-d897-494e-9fd2-1d09b32f0190 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08f3c11c-9ba0-4c53-bf31-264725e611ea (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180a07fd-1f6a-4617-b8e0-f938c65ba273 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding - Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42c4c341-8282-4961-8581-8a0430162559 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a151528-2fe0-4059-b7b7-fcb4e80a51e3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06d71a33-5578-4012-b11d-764f45bc1e6a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3276a2a4-61c7-4de6-b519-3aa8b62da88f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f069b9b-16e4-4f0e-b420-4aa02ffbb632 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1c7ec04-dd9e-400f-8f49-e900945fc61c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding: Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7a4db7f-cdac-2b36-e053-2995a90a8d64 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4abbd9d9-e9b1-463d-8f39-f3f50d80f58a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20516384-6517-48be-bd6e-718250878a76 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9965a672-7842-4926-9063-b76317c74862 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro . to human serum proteins, including albumin and α 1 -glycoprotein.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72e391aa-1a46-4589-8550-f83ac9241cf1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50369762-c7c3-d58e-e063-6294a90af8df (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c5112c0-c721-4086-9a75-3b7f931430bb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 ‑glycoprotein.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11544dea-2f5e-1536-584a-5d1f37a99770 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5336ce59-7a6c-4db9-8512-299cc5e599c0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6457d6e-5586-40e9-883d-352ee0527d80 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ebf287e-fc95-4a2c-a496-62c7cf6cbf38 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd00b7f-df07-455f-e063-6394a90a1f10 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4831735-6731-473a-b4f0-1f4a67aa7120 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:096e9438-2bed-434b-aa56-a6d55471fef1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:679e439a-d955-4b54-8236-a2ccd9a2a10a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d7a196b-91de-4753-8bb6-c6d5c668952d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53ac797d-8792-4a8c-9708-d1de3d377e8f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09fb3100-1e06-4cdc-8016-7e4f5d097490 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding: Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d09a5026-b3eb-403f-bf31-d5991a81a8ce (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0f00a25-1aec-42fd-a301-d3710ae3e1f3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70e115cc-6e9b-4b96-a1a9-779ed51ad0a7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5631bb72-798a-6efc-e054-00144ff8d46c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f302db0-1c88-44cf-8258-3c1c60afb5a4 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cece294b-c414-4832-a8a2-22fb66aabda9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:620ecf00-5473-4420-afd1-94b5b38e7301 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06394c4b-99f4-4257-bf29-53c170c5a061 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc754dff-cecb-fc6b-e053-6394a90ab371 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ce2f189-4386-4d0d-84f6-6d913ad1c09b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faf4bc0c-bf65-4a65-8f08-3d800185d6a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50117d4f-0777-54d3-e063-6394a90a857c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7b102f0-17a2-49f7-b898-cb2e0fc71b4d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9ed97dd-8041-4a02-889c-dcb8b2805f36 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1226a67f-ec09-42f6-9d1b-9ddd862ea0a0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:390c61e6-14dd-4391-45b8-0fb5f4652723 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3195db14-0cae-4b49-9fba-49b869fe92a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dced86a0-fc08-465c-897c-f8899e6206d5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b8d8da5-8c06-0942-e053-2995a90aa2c9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80816531-9db3-492b-aebc-4681bf3c1554 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e822937-9431-446f-88c4-330a25d12439 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e7929f-dec4-467d-93c2-93360884e9e9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding: Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05b0781b-50e2-4311-bde0-430b96e2ef8e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb06af33-8ff7-0b02-0029-d628f62e1382 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5dc20c8f-0d8f-400c-b850-fe1b7e3e75e3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a2a5194-b793-4c62-a177-040dad38526b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32afb28a-dc4c-4a7e-9701-1825f805e7df (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77b6ae48-8e3a-42e6-9b5a-aeed750861e8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a04a5bed-d051-4bb4-ae20-b09b10d5c181 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:10293946-5a06-4c21-9f78-941be360b09b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3daecd20-6a59-44d3-8269-4912214c08b4 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding: Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70b4bd1b-d355-189e-a414-9fff182fd1cd (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dcebc7cf-6f95-4f7a-a22b-c7d2e0f04d74 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4527c502-b28c-449f-ad2d-7daf21563cfa (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1 glycoprotein.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ded68c-1d2e-453d-b155-84c3102e1f0e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding - Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5fa64a6-3de3-4e2e-8b92-6d507fb8eee9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e111be4-28f0-c290-e063-6294a90a447f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac1651cc-4a2e-47cf-8a7e-be7ddcaf9f31 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding: Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f274f102-67ec-46e7-b248-533be2e3003b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9651816f-58f5-4bf8-8183-6f3d84d36b5c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7553d708-22a0-44ea-b907-7a86f2657f4c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be2e4325-feb9-4957-99c0-0a741a2d71a0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9de65da4-73f8-4c88-8198-c92e63224ddb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e1e767b-66a5-4f38-8142-84d40d447f92 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4dee4a1a-360c-532e-e063-6394a90a8426 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4043133-38de-4faa-bb76-8fafa5913844 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bee936b-0130-4a6b-a974-956aef5486d9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding – Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24926986-7552-4f1a-8366-f035bbd07104 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fba8d68-0663-4053-93ee-7531246fd47d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02283de9-6087-45f7-a9ce-3b082ce860de (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:224c8c17-0183-4cd7-ab9e-0062f3c624f0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef699ed0-fd9e-4580-93bb-6fd50499dbd1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a631271-9597-42a4-a924-1d06ecaba8c8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76b264ce-2a13-4511-8e21-4ffad0a327f9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a48124-0790-51c2-e053-2a95a90aa1af (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cac17277-3481-4661-935f-efc48fff534c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:daf33244-1348-4c34-b44c-9e35d5c48a3e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51b8e791-4e9a-4014-b4d8-68fd51ca889f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:887fc670-db67-4cfe-967b-46b38375dae5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:651e8c32-4519-4619-854f-4be03c6240b6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding Over the concentration range from 200 ng/mL to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f4cbf9a9-1d7f-4aa0-a18d-fba50d49bd2b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein binding —Over the concentration range from 200 to 1000 ng/mL, approximately 94.5%of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:578ca8f8-86eb-4247-a0b3-50c3837a982e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97960730-432e-4e94-bb4e-62a3157270a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd659085-c32d-4d35-9d4b-bafa2a93f1fb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding Over the concentration range from 200 ng/mL to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α1-glycoprotein.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:493a5946-e750-4500-afd1-8f3fdc1d420e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50345702-9869-5335-e054-00144ff88e88 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4f37ef1-8f5e-4318-90f1-2d8f8afb669c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 -glycoprotein.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9ee6e93-4a57-4fd1-a417-3944484dd32c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Protein Binding — Over the concentration range from 200 to 1,000 ng/mL, approximately 94.5% of fluoxetine is bound in vitro to human serum proteins, including albumin and α 1 ‑glycoprotein.

  3. Projected row 633

    Medicine slug
    fluoxetine
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    171
    Source count
    156
    Agreement rate
    1
    Recorded readings

    1. 6 to 8 hours

      Numeric value
      6
      Unit
      hours
      Source records
      156

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 156 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1c768b5-64bb-4036-aa92-797b3a5f92eb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1302fc08-d5fa-54b4-e063-6394a90a5275 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f89a5800-6fdb-4938-a28e-3bf1aeb1c21a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a32f1a0b-a9ee-883a-e053-2a95a90a8c12 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1409772-e719-67f5-e053-2995a90ab5b6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:369dbfba-9de4-433c-8680-2ec047b8f8d9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18e9f7f2-2d33-d139-e063-6294a90a3012 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ffe57c3-6f70-4075-aacb-d87a3990fdea (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability - In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to55 ng/mL are observed after 6 to 8 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c88f33ed-6dfb-4c5e-bc01-d8e36dd97299 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6b9c2d73-866b-44c4-8718-e7e4a9a0fb55 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability – In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:851c4cfb-e1f0-4087-b13d-c07c25fea37d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c8970ad-2266-4653-b7eb-4c79ba926d89 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b07f9eab-44ac-4667-bd46-52d736daa5d6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d121146e-7439-4169-a421-dab7b882b8aa (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8666383-462d-4a21-8f49-1d572da386d1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3da881-475d-cdee-e063-6394a90aee99 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:992060ee-fb4e-4c6d-9ffe-30902bc63af2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0608d9-1ae3-43be-8a20-e9f34e955862 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583c5021-2948-7db4-e063-6294a90ae7dc (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f4e4e9f-9ded-452f-b3ef-ab6aa9c72952 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability - In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5a267cb-08bd-4530-a7a8-2bceddd828e5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45454555-7402-41cb-a452-e6a76e04f387 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e15646e0-a431-4b3d-8d6f-7a3d0dadfcc6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78994632-74b3-951c-e053-2a91aa0ac1c8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c4eeae3d-ae56-4e7e-b07d-02851f12039f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0cba1992-3990-42a1-9d9a-77b593bbb02e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f917063a-226e-0978-e053-6294a90aeb4b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ada19ae4-f3bd-47fa-a5c3-a6bb3aa34943 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58b39e6a-3aae-4551-b081-586a4506aef2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability: In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb66a702-7670-4a73-98fb-0e63151a1ffb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca749349-d0e1-4b7c-b4c0-e392e72cf0f6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dfae4357-b6f9-9a30-e053-2995a90a2667 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da6b9b19-2ea1-9a39-e053-2995a90ad730 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d34362ed-e821-4c55-9f8c-3dfb772b1b2a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a07ebe9-3661-4a48-b8af-9b228875166a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1b40d46-5233-49d7-9833-762cb6999012 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5020d0d6-969e-b4cd-e063-6294a90af9d2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50253c6e-de36-05e6-e063-6294a90ad7a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:023cef65-c9c2-4d70-af66-198fb1b57714 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54d9f02c-95ea-99b1-e063-6294a90a9140 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:647e17f5-a15a-4e77-922c-24a5db2118bc (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ccada47-7eb9-285d-5059-06afb4466114 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d5c10a-0cfc-4b89-942c-0fb5c67ae409 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da785a8a-d897-494e-9fd2-1d09b32f0190 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08f3c11c-9ba0-4c53-bf31-264725e611ea (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4915e22f-cecb-4261-8389-9bb417a20e82 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180a07fd-1f6a-4617-b8e0-f938c65ba273 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability - In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42c4c341-8282-4961-8581-8a0430162559 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a151528-2fe0-4059-b7b7-fcb4e80a51e3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06d71a33-5578-4012-b11d-764f45bc1e6a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3276a2a4-61c7-4de6-b519-3aa8b62da88f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9f069b9b-16e4-4f0e-b420-4aa02ffbb632 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cca9edf9-2454-4bf9-98e8-c531a8f5dc42 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c1c7ec04-dd9e-400f-8f49-e900945fc61c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability: In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7a4db7f-cdac-2b36-e053-2995a90a8d64 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b8fe00e-7a2f-486b-9b72-465a494d8939 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4abbd9d9-e9b1-463d-8f39-f3f50d80f58a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20516384-6517-48be-bd6e-718250878a76 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9965a672-7842-4926-9063-b76317c74862 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72e391aa-1a46-4589-8550-f83ac9241cf1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50369762-c7c3-d58e-e063-6294a90af8df (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d26f7450-7650-43df-a63b-1fe2472882a9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c5112c0-c721-4086-9a75-3b7f931430bb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11544dea-2f5e-1536-584a-5d1f37a99770 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c856d72f-4a1a-4f75-ae54-c4ac83ddcfa1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics S ystemic Bioavailability – In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a6457d6e-5586-40e9-883d-352ee0527d80 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ebf287e-fc95-4a2c-a496-62c7cf6cbf38 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd00b7f-df07-455f-e063-6394a90a1f10 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4831735-6731-473a-b4f0-1f4a67aa7120 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:096e9438-2bed-434b-aa56-a6d55471fef1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef0fa849-a3a0-45d2-9258-da2d46bee089 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:679e439a-d955-4b54-8236-a2ccd9a2a10a (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d7a196b-91de-4753-8bb6-c6d5c668952d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53ac797d-8792-4a8c-9708-d1de3d377e8f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09fb3100-1e06-4cdc-8016-7e4f5d097490 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability: In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0f00a25-1aec-42fd-a301-d3710ae3e1f3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70e115cc-6e9b-4b96-a1a9-779ed51ad0a7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5631bb72-798a-6efc-e054-00144ff8d46c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f302db0-1c88-44cf-8258-3c1c60afb5a4 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d5d03ff-0d0c-429f-b747-31ff3465d39d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cece294b-c414-4832-a8a2-22fb66aabda9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:620ecf00-5473-4420-afd1-94b5b38e7301 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability – In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a08dadff-f209-48dc-b597-6f085be13640 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06394c4b-99f4-4257-bf29-53c170c5a061 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc754dff-cecb-fc6b-e053-6394a90ab371 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aae4e339-5244-f6f9-e053-2995a90a42ce (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ce2f189-4386-4d0d-84f6-6d913ad1c09b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faf4bc0c-bf65-4a65-8f08-3d800185d6a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50117d4f-0777-54d3-e063-6394a90a857c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7b102f0-17a2-49f7-b898-cb2e0fc71b4d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48705e4f-c3ee-af78-e063-6394a90ad052 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability— In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57f21f2b-0ec2-49dc-911a-806e5ae880c2 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c56a437-f6bf-4ac8-b1d9-fc8a605a97e7 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1226a67f-ec09-42f6-9d1b-9ddd862ea0a0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:390c61e6-14dd-4391-45b8-0fb5f4652723 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3195db14-0cae-4b49-9fba-49b869fe92a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a408c325-d2d5-4e88-85ce-96913eb58183 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5035f61-693e-4386-8a07-3c36a6a46917 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3453755b-3ed6-47a3-b4c7-c64758e7784c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b8d8da5-8c06-0942-e053-2995a90aa2c9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:80816531-9db3-492b-aebc-4681bf3c1554 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e822937-9431-446f-88c4-330a25d12439 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e7929f-dec4-467d-93c2-93360884e9e9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability: In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:05b0781b-50e2-4311-bde0-430b96e2ef8e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cdf3b608-e14c-474b-b80e-01ac5f701866 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bb06af33-8ff7-0b02-0029-d628f62e1382 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5dc20c8f-0d8f-400c-b850-fe1b7e3e75e3 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a2a5194-b793-4c62-a177-040dad38526b (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9de93d4-2edc-2838-e053-2995a90a8ed6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32afb28a-dc4c-4a7e-9701-1825f805e7df (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a04a5bed-d051-4bb4-ae20-b09b10d5c181 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3daecd20-6a59-44d3-8269-4912214c08b4 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability: In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:70b4bd1b-d355-189e-a414-9fff182fd1cd (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4527c502-b28c-449f-ad2d-7daf21563cfa (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability - In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ded68c-1d2e-453d-b155-84c3102e1f0e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability - In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5fa64a6-3de3-4e2e-8b92-6d507fb8eee9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e111be4-28f0-c290-e063-6294a90a447f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac1651cc-4a2e-47cf-8a7e-be7ddcaf9f31 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability: In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9651816f-58f5-4bf8-8183-6f3d84d36b5c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5d49dee-a7de-44d8-80b5-1aeb89e76938 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7553d708-22a0-44ea-b907-7a86f2657f4c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be2e4325-feb9-4957-99c0-0a741a2d71a0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability – In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be4c5102-e0aa-3b89-e053-2a95a90a5d9d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9de65da4-73f8-4c88-8198-c92e63224ddb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability – In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e1e767b-66a5-4f38-8142-84d40d447f92 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab1eec9d-f755-81a2-e053-2a95a90acb3c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4dee4a1a-360c-532e-e063-6394a90a8426 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4043133-38de-4faa-bb76-8fafa5913844 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7bee936b-0130-4a6b-a974-956aef5486d9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability – In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:24926986-7552-4f1a-8366-f035bbd07104 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23899405-007b-48d9-82a9-a530b8e90784 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0259db51-e1ff-6e7a-e063-6394a90abace (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fba8d68-0663-4053-93ee-7531246fd47d (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02283de9-6087-45f7-a9ce-3b082ce860de (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:224c8c17-0183-4cd7-ab9e-0062f3c624f0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef699ed0-fd9e-4580-93bb-6fd50499dbd1 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:06582152-d7d3-4e87-8c13-a4416a6ec927 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a7bea6e9-cf90-a963-e053-2a95a90a1068 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:76b264ce-2a13-4511-8e21-4ffad0a327f9 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2a48124-0790-51c2-e053-2a95a90aa1af (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cac17277-3481-4661-935f-efc48fff534c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:daf33244-1348-4c34-b44c-9e35d5c48a3e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e83e2220-d32a-472c-bd9f-b87d0cf8858f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:51b8e791-4e9a-4014-b4d8-68fd51ca889f (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5386a140-7c5b-5959-e063-6294a90a2ad0 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:887fc670-db67-4cfe-967b-46b38375dae5 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec608267-9c00-4d5c-a9ed-d89503f93d28 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:651e8c32-4519-4619-854f-4be03c6240b6 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      149. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:578ca8f8-86eb-4247-a0b3-50c3837a982e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      150. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97960730-432e-4e94-bb4e-62a3157270a8 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      151. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd659085-c32d-4d35-9d4b-bafa2a93f1fb (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs. 12.3 Pharmacokinetics Systemic Bioavailability In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      152. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:493a5946-e750-4500-afd1-8f3fdc1d420e (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      153. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:50345702-9869-5335-e054-00144ff88e88 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      154. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4f37ef1-8f5e-4318-90f1-2d8f8afb669c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.
      155. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e6b9d55-f9bb-4bf2-bc6c-975cc0d94d23 (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 ng/mL to 55 ng/mL are observed after 6 to 8 hours.
      156. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9ee6e93-4a57-4fd1-a417-3944484dd32c (opens source in a new tab)

        Fluoxetine label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Systemic Bioavailability — In man, following a single oral 40 mg dose, peak plasma concentrations of fluoxetine from 15 to 55 ng/mL are observed after 6 to 8 hours.

  4. Projected row 634

    Medicine slug
    flurbiprofen
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 96%

      Numeric value
      96
      Unit
      %
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ebf7427-eaae-4035-a6b2-0ea6381e8763 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        f Distribution (Vz/F, L) 14 (3) 12 (5) 10 14 Terminal Elimination Half-life (t ½ , h) 7.5 (0.8) 5.8 (1.9) 3.3 Value for S-flurbiprofen 5.4 Absorption The mean oral bioavailability of flurbiprofen from flurbiprofen tablets 100 mg is 96% relative to an oral solution.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6c6a0daa-de1b-5455-e053-2991aa0a4cf8 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        f Distribution (Vz/F, L) 14 (3) 12 (5) 10 14 Terminal Elimination Half-life (t ½ , h) 7.5 (0.8) 5.8 (1.9) 3.3 Value for S-flurbiprofen 5.4 Absorption The mean oral bioavailability of flurbiprofen from flurbiprofen tablets 100 mg is 96% relative to an oral solution.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4670cf21-eb0e-4f5a-ab22-41af85733525 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        f Distribution (Vz/F, L) 14 (3) 12 (5) 10 14 Terminal Elimination Half-life (t ½ , h) 7.5 (0.8) 5.8 (1.9) 3.3 Value for S-flurbiprofen 5.4 Absorption The mean oral bioavailability of flurbiprofen from flurbiprofen tablets 100 mg is 96% relative to an oral solution.

  5. Projected row 635

    Medicine slug
    flurbiprofen
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ebf7427-eaae-4035-a6b2-0ea6381e8763 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        Flurbiprofen is rapidly and non-stereoselectively absorbed from flurbiprofen, with peak plasma concentrations occurring at approximately 2 hours (see Table 2 ).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6c6a0daa-de1b-5455-e053-2991aa0a4cf8 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        Flurbiprofen is rapidly and non-stereoselectively absorbed from flurbiprofen, with peak plasma concentrations occurring at approximately 2 hours (see Table 2).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4670cf21-eb0e-4f5a-ab22-41af85733525 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        Flurbiprofen is rapidly and non-stereoselectively absorbed from flurbiprofen, with peak plasma concentrations occurring at approximately 2 hours (see Table 2 ).

  6. Projected row 636

    Medicine slug
    flurbiprofen
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    7
    Source count
    3
    Agreement rate
    1
    Recorded readings

    1. 0.12 L/kg

      Numeric value
      0.12
      Unit
      L/kg
      Source records
      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ebf7427-eaae-4035-a6b2-0ea6381e8763 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vz/F) of both R- and S-flurbiprofen is approximately 0.12 L/kg.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6c6a0daa-de1b-5455-e053-2991aa0a4cf8 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vz/F) of both R- and S-flurbiprofen is approximately 0.12 L/kg.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4670cf21-eb0e-4f5a-ab22-41af85733525 (opens source in a new tab)

        Flurbiprofen label

        Version not recorded · Effective date not recorded

        Distribution The apparent volume of distribution (Vz/F) of both R- and S-flurbiprofen is approximately 0.12 L/kg.

  7. Projected row 637

    Medicine slug
    flutamide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 6 hours

      Numeric value
      6
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a905e25-42b6-4937-a689-f01a8f22e644 (opens source in a new tab)

        Flutamide label

        Version not recorded · Effective date not recorded

        The plasma half-life for the alpha-hydroxylated metabolite of Eulexin ® is approximately 6 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56b6ba36-9b49-4422-a2a4-7bfa0d941a5d (opens source in a new tab)

        Flutamide label

        Version not recorded · Effective date not recorded

        The plasma half-life for the alpha-hydroxylated metabolite of Eulexin™ is approximately 6 hours.

  8. Projected row 638

    Medicine slug
    fluvastatin
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    11
    Source count
    11
    Agreement rate
    0.636364
    Recorded readings

    1. 24%

      Numeric value
      24
      Unit
      %
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02db192f-0cdb-4aef-aa6e-cfb9b6cb0101 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0a7247c-5d83-4bc1-840f-c58314d14195 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9%-50%) after administration of a 10 mg dose.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5e8d1da-8911-42db-9f90-cba04b28d011 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48801d7c-99ac-4a78-b714-299e2a5562ea (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccd6bbe1-e293-4e1c-9ec4-e6c217612e77 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aad8b373-0aec-4efb-8e61-3d8114b31127 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3c9f49c-051c-451a-8749-1a7bee820078 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.

    2. 29%

      Numeric value
      29
      Unit
      %
      Source records
      4

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 4 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab4296c-87c2-4c64-b218-d620eef51310 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The mean relative bioavailability of the extended-release tablet is approximately 29% (range, 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:726ea2db-f1b0-4b73-a515-02157db88a42 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The mean relative bioavailability of the XL tablet is approximately 29% (range, 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc55110f-1ad6-4f97-840d-62b3a5ac415a (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The mean relative bioavailability of the extended-release tablet is approximately 29% (range, 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3565bfd3-ef9f-456d-b4be-a294a7a0f01c (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The mean relative bioavailability of the extended-release tablet is approximately 29% (range, 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions.

  9. Projected row 639

    Medicine slug
    fluvastatin
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    11
    Source count
    11
    Agreement rate
    1
    Recorded readings

    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab4296c-87c2-4c64-b218-d620eef51310 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:726ea2db-f1b0-4b73-a515-02157db88a42 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02db192f-0cdb-4aef-aa6e-cfb9b6cb0101 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0a7247c-5d83-4bc1-840f-c58314d14195 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5e8d1da-8911-42db-9f90-cba04b28d011 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48801d7c-99ac-4a78-b714-299e2a5562ea (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc55110f-1ad6-4f97-840d-62b3a5ac415a (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3565bfd3-ef9f-456d-b4be-a294a7a0f01c (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccd6bbe1-e293-4e1c-9ec4-e6c217612e77 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aad8b373-0aec-4efb-8e61-3d8114b31127 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3c9f49c-051c-451a-8749-1a7bee820078 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        The elimination half-life (t 1/2 ) of fluvastatin is approximately 3 hours.

  10. Projected row 640

    Medicine slug
    fluvastatin
    Compared field
    tMax
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    11
    Source count
    11
    Agreement rate
    1
    Recorded readings

    1. 3 hours

      Numeric value
      3
      Unit
      hours
      Source records
      11

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 11 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab4296c-87c2-4c64-b218-d620eef51310 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:726ea2db-f1b0-4b73-a515-02157db88a42 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Fluvastatin administered as LESCOL XL 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02db192f-0cdb-4aef-aa6e-cfb9b6cb0101 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0a7247c-5d83-4bc1-840f-c58314d14195 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f5e8d1da-8911-42db-9f90-cba04b28d011 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48801d7c-99ac-4a78-b714-299e2a5562ea (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc55110f-1ad6-4f97-840d-62b3a5ac415a (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Fluvastatin administered as fluvastatin sodium extended-release tablets, 80 mg reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3565bfd3-ef9f-456d-b4be-a294a7a0f01c (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics Absorption Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low-fat meal, or 2.5 hours after a low-fat meal.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ccd6bbe1-e293-4e1c-9ec4-e6c217612e77 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aad8b373-0aec-4efb-8e61-3d8114b31127 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3c9f49c-051c-451a-8749-1a7bee820078 (opens source in a new tab)

        Fluvastatin label

        Version not recorded · Effective date not recorded

        Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=630

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy